Lymphoma

Rituximab in the Treatment of Follicular Lymphoma: the Future of Biosimilars in the Evolving Therapeutic Landscape

Rituximab in the Treatment of Follicular Lymphoma: the Future of Biosimilars in the Evolving Therapeutic Landscape

[Cancer Management and Research] This research summarizes the role of rituximab across the spectrum of FL treatment and the evolving therapeutic landscape with the emergence of novel agents currently in clinical development.

CAR T Cells: Keeping Pace With Adverse Effects of an Emerging Therapy

CAR T Cells: Keeping Pace With Adverse Effects of an Emerging Therapy

By

The oncology nurses' role in monitoring and early recognition of the signs and symptoms of CAR T-cell toxicities is significant considering the potential severity of these adverse effects.

Novel Approach Prevents GVHD After Hematopoietic Stem Cell Transplantation

Novel Approach Prevents GVHD After Hematopoietic Stem Cell Transplantation

By

An international team developed an approach to hematopoietic stem cell transplantation that prevents GVHD while preserving the benefits of the therapy.

Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors

Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors

By

Hodgkin lymphoma survivors are at higher risk of second cancers, and that risk is even higher in those with a first-degree relative with cancer.

Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL

Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL

By

Lenalidomide maintenance appears efficacious for relapsed diffuse large B cell lymphoma.

Treatment Outcomes Were Unchanged by Brentuximab Vedotin (BV)-induced Peripheral Neuropathy

Treatment Outcomes Were Unchanged by Brentuximab Vedotin (BV)-induced Peripheral Neuropathy

By

Patients who were surveyed reported that the benefits of treatment with BV outweighed its risks.

Pembrolizumab Active in Refractory NK/T-cell Lymphoma

Pembrolizumab Active in Refractory NK/T-cell Lymphoma

By

PD-1 blockade with pembrolizumab was active and induced durable responses in patients with natural killer (NK)/T-cell lymphoma failing L-asparaginase.

Hepatitis C Virus Associated With Increased Risk of Variety of Cancers

Hepatitis C Virus Associated With Increased Risk of Variety of Cancers

By

Researchers have found that hepatitis C virus infection is associated with an elevated risk for developing bile duct cancers and diffuse large B-cell lymphoma.

Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma

Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma

[OncoTargets and Therapy] This research examines the efficacy and safety of recombinant human endostatin in combination with CHOP regimen (ECHOP) for patients with peripheral T cell lymphoma.

O-DHAP and R-DHAP Equivalent As Salvage Therapy for R/R DLBCL

O-DHAP and R-DHAP Equivalent As Salvage Therapy for R/R DLBCL

By

Researchers sought to compare the efficacy of O-DHAP with R-DHAP as salvage treatment, followed by autologous hematopoietic cell transplantation.

Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma

Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma

By

The patient's history and current blood work results indicated a dangerously high potassium level. But a meticulously handled redraw proved it false.

Rituximab With High-dose Sequential Chemo Fails to Improve DLBCL Outcomes

Rituximab With High-dose Sequential Chemo Fails to Improve DLBCL Outcomes

By

Frontline treatment with rituximab plus high-dose sequential chemotherapy with autologous HSCT failed to improve progression-free or overall survival compared with R-CHOP in patients with diffuse large B-cell lymphoma.

Severe Fatigue Associated With Unemployment in Hodgkin Lymphoma Survivors

Severe Fatigue Associated With Unemployment in Hodgkin Lymphoma Survivors

By

Severe fatigue is associated with unemployment and financial problems in survivors of Hodgkin lymphoma, highlighting the need for clinicians to address fatigue in these patients.

Ciprofloxacin May Prevent Bacteremia in Patients Undergoing Auto-HSCT

Ciprofloxacin May Prevent Bacteremia in Patients Undergoing Auto-HSCT

By

Antibacterial prophylaxis with the flouroquinolone, ciprofloxacin, substantially reduced the risk of bacteremia and neutropenic fever in patients with multiple myeloma or lymphoma undergoing high-dose chemotherapy and auto-HSCT.

Carmustine Infusion Reactions Occur Despite Extending Infusion Duration

Carmustine Infusion Reactions Occur Despite Extending Infusion Duration

By

Infusion reactions during administration of high-dose carmustine as part of the BEAM conditioning regimen are common and do not appear to be reduced by modestly extending the duration of infusion or giving premedications.

Cancer-related Fatigue Common in Hodgkin Lymphoma Survivors

Cancer-related Fatigue Common in Hodgkin Lymphoma Survivors

By

There is a high incidence of severe acute and persistent cancer-related fatigue in survivors of Hodgkin lymphoma, regardless of tumor stage or treatment.

Monoclonal Antibody Shows Promise in Aggressive R/R Adult T-cell Leukemia/Lymphoma

Monoclonal Antibody Shows Promise in Aggressive R/R Adult T-cell Leukemia/Lymphoma

By

Mogamulizumab induced an encouraging response rate in patients with relapsed/refractory adult T-cell leukemia/lymphoma.

PET-CT Can Inform Decision to Omit Bleomycin in Hodgkin Lymphoma Treatment to Reduce Toxicity

PET-CT Can Inform Decision to Omit Bleomycin in Hodgkin Lymphoma Treatment to Reduce Toxicity

By

Omitting bleomycin from the treatment regimen for Hodgkin lymphoma in patients with negative findings on an interim PET scan led to a lower incidence of pulmonary toxic effects without significantly lowering treatment efficacy.

Study Confirms Lenalidomide Effective for Diffuse Large B-Cell Lymphoma

Study Confirms Lenalidomide Effective for Diffuse Large B-Cell Lymphoma

By

Lenalidomide is an effective treatment option with limited and reversible toxicities for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), a 'real-world' study has shown.

Autologous Stem Cell Transplant Safe as Standard of Care in Patients With HIV-Associated Lymphoma

Autologous Stem Cell Transplant Safe as Standard of Care in Patients With HIV-Associated Lymphoma

By

Recent results from a multicenter, phase 2 trial suggest that patients with HIV and aggressive lymphoma should receive autologous stem cell transplant as standard of care. Risk of serious complications after transplant in these patients is equal to that of patients without HIV.

aHSCT Should Be Standard of Care for HIV-Related Lymphoma

aHSCT Should Be Standard of Care for HIV-Related Lymphoma

Patients living with HIV are at high risk for lymphoma,according to recent study data, and recent autologous hematopoietic stem-cell transplantation may be preferable for these patients.

Alemtuzumab + CHOP for Peripheral T Cell Lymphoma: Higher Remission, But Not Survival

Alemtuzumab + CHOP for Peripheral T Cell Lymphoma: Higher Remission, But Not Survival

By

When added to the CHOP regimen, alemtuzumab increases remission rates in elderly patients with peripheral T cell lymphoma, final analysis of the international ACT-2 phase 3 trial presented at the ASCO 2016 Annual Meeting has shown.

Deferred Therapy Linked to Improved Survival for Newly Diagnosed Mantle Cell Lymphoma

Deferred Therapy Linked to Improved Survival for Newly Diagnosed Mantle Cell Lymphoma

By

Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma.

Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas

Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas

[Blood and Lymphatic Cancer: Targets and Therapy] This research examines the clinical trial data using idelalisib as monotherapy or in combination with rituximab for the treatment of indolent B-cell malignancies.

Patients With Hodgkin Lymphoma Resistant to Brentuximab Vedotin Have Poor Outcomes

Patients With Hodgkin Lymphoma Resistant to Brentuximab Vedotin Have Poor Outcomes

By

Patients with classical Hodgkin lymphoma who are resistant to the CD30-directed antibody-drug conjugate brentuximab vedotin have poor outcomes.

Gut Bacteria Could Reduce GVHD in Patients Undergoing Bone Marrow Transplantation

Gut Bacteria Could Reduce GVHD in Patients Undergoing Bone Marrow Transplantation

By

A short-chain fatty acid made by bacteria in the gut could play an important role in GVHD after allogeneic bone marrow transplant in mice. In human patients who receive bone marrow transplants, GVHD can cause severe gut damage.

Temsirolimus Effective as Salvage Treatment in Patients With Relapsed/Refractory PCNSL

Temsirolimus Effective as Salvage Treatment in Patients With Relapsed/Refractory PCNSL

By

A weekly dose of temsirolimus 75 mg was found to be active in patients with relapsed/refractory primary CNS lymphoma (PCNSL); however, only some patients achieved long-term control.

Hair, Nail Abnormalities Common With Ibrutinib Therapy

Hair, Nail Abnormalities Common With Ibrutinib Therapy

By

Hair and nail abnormalities are commonly associated with the Bruton tyrosine kinase inhibitor ibrutinib.

Reduced Intensity Salvage Allo-HCT Effective for Follicular Lymphoma

Reduced Intensity Salvage Allo-HCT Effective for Follicular Lymphoma

By

Reduced intensity allogeneic hematopoietic cell transplantation (HCT) is an effective salvage treatment strategy in patients with follicular lymphoma.

Protein Tag Improves T Cell Immunotherapy Against Lymphoma in an Animal Model

By

A new approach in T cell immunotherapy uses a small protein tag to hasten and improve the immunotherapy's ability to attack cancer cells.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs